A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)

Clinical trial NCT05849480 · RECRUITING

Trial details

NCT number: NCT05849480
Sponsor: National Cancer Institute (NCI)
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Biliary Cancer Bile Duct Cancer Cancer of the Bile Duct

Start date: 2024-05-08
Primary completion: 2040-06-01
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.